Yttrium-90 selective internal radiotherapy in conversion treatment of unresectable hepatocellular carcinoma:research progress
10.16781/j.CN31-2187/R.20240273
- VernacularTitle:钇-90选择性内放射治疗在不可切除肝细胞癌转化治疗中的研究进展
- Author:
Man ZHAO
1
;
Qianwen NI
;
Xianjie PIAO
;
Xiaoqin WU
;
Rui ZHOU
;
Kaiting ZHANG
;
Zhenguang WANG
;
Minghao ZOU
;
Wenxuan ZHOU
;
Fuchen LIU
;
Hui LIU
Author Information
1. 上海理工大学健康科学与工程学院,上海 200093;海军军医大学(第二军医大学)第三附属医院肝外三科,上海 200438
- Keywords:
yttrium-90;
selective internal radiotherapy;
liver neoplasms;
unresectable hepatocellular carcinoma;
conversion therapy
- From:
Academic Journal of Naval Medical University
2025;46(2):189-197
- CountryChina
- Language:Chinese
-
Abstract:
Yttrium-90(90Y)selective internal radiation therapy(SIRT)is an emerging modality for the treatment of hepatocellular carcinoma(HCC),leveraging the nuclide 90Y to deliver targeted radiation therapy.90Y has a long half-life and can be used to selectively ablate tumor cells by high-energy beta rays.It has high biological effectiveness and robust local control capabilities.In recent years,with the continuous advancement of basic and clinical research,the application of 90Y-SIRT in the conversion treatment of unresectable HCC(uHCC)has made significant progress.However,challenges remain in the clinical application of 90Y-SIRT,including how to improve the efficacy of conversion therapy and how to optimize therapy regimens.This review aims to summarize the research progress of90Y-SIRT in the conversion therapy of uHCC.
